Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. - Wikidata - awgldk - TriplyDB

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

http://www.wikidata.org/entity/Q41953550

about

Presymptomatic studies in ALS: rationale, challenges, and approach Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys Neuroimaging biomarkers of neurodegenerative diseases and dementia Impairment of vowel articulation as a possible marker of disease progression in Parkinson's disease.The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.Neuroimaging and therapeutics in movement disorders.The role of biomarkers and imaging in Parkinson's disease.[(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites.[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.Neuroimaging in pre-motor Parkinson's disease Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease.REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century.Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson's disease Defining at-risk populations for Parkinson's disease: lessons from ongoing studies.Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study.On a basal ganglia role in learning and rehearsing visual-motor associations.Genetics of parkinsonism.Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease.The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling.The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS.[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation Changes in network activity with the progression of Parkinson's disease.Molecular profiling approaches for identifying novel biomarkers.Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease Flanker compatibility effects in patients with Parkinson's disease: impact of target onset delay and trial-by-trial stimulus variation.Premotor Parkinson's disease: concepts and definitions Fully Automated Quantification of the Striatal Uptake Ratio of [(99m)Tc]-TRODAT with SPECT Imaging: Evaluation of the Diagnostic Performance in Parkinson's Disease and the Temporal Regression of Striatal Tracer Uptake.Positron emission tomography imaging of transplant function.Longitudinal deformation-based morphometry reveals spatio-temporal dynamics of brain volume changes in patients with corticobasal syndrome The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.Biomarkers in Parkinson's disease.Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function.PET radiopharmaceuticals for probing enzymes in the brain Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis

P2860

Q26824988-43A67F97-E023-4C04-803D-ADA43B8006D6 Q27316473-CBA2E230-F55C-41B5-B969-227B179CA58C Q27691820-4584AF93-A7A8-4FC1-8E99-A793030530A7 Q30469875-F5B05271-C866-476D-BB19-F999CA1DD534 Q30635471-77BDA97F-F367-4490-B076-C0BC0621F933 Q30829363-EE2591F6-03BF-4CD6-B587-B472B98F9002 Q30989947-0A72893C-7ED3-4598-B0DD-0099A007853D Q31041660-46B82949-3364-44D6-8BC5-5A9F4C41A848 Q31911300-243B78A2-E9C8-46A9-A2D1-2D2F34413FAB Q32052220-3938B8E6-44EC-41BF-9087-67358099D9A8 Q33676222-73ACB066-9E4F-4B4D-9E66-E3901EB3223F Q33704605-6BFF384C-B021-45D3-86C1-5F2BC0F84172 Q34053259-B4E0FE88-42A4-4E67-BE64-275118DE063B Q34181259-1339B09D-3722-4973-B46E-F7248F4D0BB5 Q34234632-4A0750C5-C150-450B-B876-CEB515DE79EF Q34464847-269F00B7-9FAE-44CA-9CE8-7DCFBF71EEDC Q34725942-2CA9F9EE-807B-4F88-BD7A-A4596F943502 Q34811944-4474DE68-A26A-49F6-9A4E-62E136AADFC4 Q34827117-0EB656B7-2E22-4800-87A5-B629071E277F Q34985170-CB8015AA-3CFE-46A2-B846-60705A292A89 Q35034718-3B28F993-E8F5-4B75-AE6A-3BBCEFCBAB50 Q35089830-D0B178A8-CC72-495E-82E6-26DFCF9657E1 Q35240090-42039035-3C3F-4641-9045-249D31DA3274 Q35471953-9DEE3A3E-F16F-424D-940A-35C76EDE0778 Q35490116-3703DA3A-0CD6-45A2-8019-B20C647A7F38 Q35679748-CC77230B-57BE-40EB-B2A2-C894054619C6 Q35684838-1C6812BE-F37F-4433-8087-93E3E79B6352 Q35759065-893D810F-D486-4C3F-9F6A-53F7821016A9 Q35792950-3EF6379B-7185-4FC9-9B69-D229A29F7048 Q35910731-B5181960-787C-4195-AAA7-A6A9B2C3E50C Q36022062-A3F5217F-F513-4F1B-A33E-3E735A7928F5 Q36045402-41DEED55-BC48-4F5C-8029-14BBA5DC9F58 Q36123562-306F8B46-1D10-4469-8836-50F722BDC7ED Q36124421-A5D3735A-A4BF-4F06-B0E9-F1292DED9F5A Q36129732-AA780FAF-2135-4A43-852A-F3B07C922F05 Q36485934-6EA3EA3C-AD3D-4ACE-A2ED-89F12DAEEB50 Q36511295-317879F9-BDA6-4128-864B-1797F76D6DE7 Q36647035-2D349DFE-BA02-47A8-8F5A-CF9DED72F2D7 Q36769219-40A21F96-2113-4AF6-94CC-2FD681256BAD Q37022940-0D2198ED-F714-4682-8083-F768166BA59D

P2860

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

http://www.wikidata.org/entity/Q41953550

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Measuring the rate of progress ...... 's disease with [18F]dopa PET.

@en

type

label

Measuring the rate of progress ...... 's disease with [18F]dopa PET.

@en

prefLabel

Measuring the rate of progress ...... 's disease with [18F]dopa PET.

@en

P1433

Q41953550-2868335E-AF4E-4368-868D-2AB75A185630

P1476

Q41953550-8E4F46E8-C4FC-491B-8227-C9C82476E40E

P2093

Q41953550-07892065-F7A3-46AD-BA22-8E8587451B3A

Q41953550-3197A50B-E9F5-4245-8259-AC1C420527FB

Q41953550-82D68852-4ADF-4811-A159-B86AEDDAB2A9

Q41953550-9438F2E8-2FAB-4563-B767-A87C7E4CFC18

Q41953550-E5B6D3A7-0B64-4F01-A684-AA9ED587DB8F

P2860

Q41953550-0D6000DF-D8F5-47F8-A1A0-8C0F4D6106CB

Q41953550-0D838467-D663-41EA-BABD-D579C4C9AE76

Q41953550-1F064DCF-755A-4016-BAE7-94FB1DE3517A

Q41953550-396F59BD-CC8E-4481-8E49-275BF387F35A

Q41953550-48FA8C99-41A8-46D1-95D1-F63F41A502EE

Q41953550-56A371D6-08DC-4418-A3F4-AE791471EB2C

Q41953550-5D04849A-5BC1-497F-A132-A4BCB302351A

Q41953550-72CD89B2-B3BB-4A26-BA84-85F887C41626

Q41953550-83A49519-FE1D-4A84-83A4-C1A5020F183D

Q41953550-8813607E-118D-4F7B-B580-20393ACAD0BA

P304

Q41953550-0D9E642D-9946-4724-B5E0-EF64E93CEA11

P31

Q41953550-1C925E47-150F-43CB-A4AF-AD21F50E381C

P356

Q41953550-194178A6-B91E-4985-BEE3-B249CC0CA68D

P407

Q41953550-3BE06C5A-D9FB-4D50-B353-875F5966CD46

P433

Q41953550-8F63A88B-80A8-41A2-9A80-3C49B27E187A

P478

Q41953550-0F8D5A34-2759-4AF9-84A4-196D5E1CC891

P577

Q41953550-6AE8523A-3E60-4C0B-B8DD-0D495472BDC4

P5875

Q41953550-937A17C7-9089-40BF-A171-CDD303BE3B2F

P698

Q41953550-503D6A45-2E95-418D-91AA-9AEB3BEDE813

P932

Q41953550-76AE4F3F-4637-4A3C-A835-3E9299DF5E9A

P356

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Measuring the rate of progress ...... 's disease with [18F]dopa PET.

@en

P2093

Bailey DL

http://www.w3.org/2001/XMLSchema#string

Brooks DJ

http://www.w3.org/2001/XMLSchema#string

Morrish PK

http://www.w3.org/2001/XMLSchema#string

Rakshi JS

http://www.w3.org/2001/XMLSchema#string

Sawle GV

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinsonism: onset, progression and mortality

Aetiology of Parkinson's disease

Ageing and Parkinson's disease: substantia nigra regional selectivity

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

Clinical and [18F] dopa PET findings in early Parkinson's disease

When does Parkinson's disease begin?

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.

Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects.

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.

P304

314-319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.64.3.314

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

1998-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247695499

http://www.w3.org/2001/XMLSchema#string

P698

9527140

http://www.w3.org/2001/XMLSchema#string

P932

2170010

http://www.w3.org/2001/XMLSchema#string